TD Cowen lowered the firm’s price target on Teladoc to $9 from $15 and keeps a Hold rating on the shares. The firm said while they saw positive 2Q results, worsening CAC trends led to declines in BH users and revenues with management withdrawing consolidated and BH guides.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- TDOC Earnings: Teladoc Health Stock Crashes on Mixed Q2 Results, Withdraws Outlook
- Options Volatility and Implied Earnings Moves Today, July 31, 2024
- Options Volatility and Implied Earnings Moves This Week, July 29 – August 02, 2024
- TDOC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Teladoc call volume above normal and directionally bullish